HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022
Aditya Bardia, MD of Mass General discusses the
GS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
HER2-Low: Anastrozole TRIO-US B-12 TALENT Aditya Bardia SABCS 2022
